Todos os posts
Diretriz de consenso | Diagnóstico da ulceração oral complicada e difícil.
13 Jun, 2022 | 14:46h#ASCO22 – Estudo randomizado | Trastuzumabe deruxtecam no câncer de mama avançado previamente tratado com baixo HER2.
13 Jun, 2022 | 14:45hTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
DESTINY-Breast04: In a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician’s choice of chemo among patients with HER2-low breast cancer. #ASCO22 https://t.co/bgheQ1yolb pic.twitter.com/nfRMcIh9Ly
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Estudo randomizado | Ibrutinibe com bendamustina e rituximabe no linfoma de células do manto.
13 Jun, 2022 | 14:43hIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center
#ASCO22 – Estudo de braço único fase 2 | Adagrasibe em câncer de pulmão de não pequenas células abrigando uma mutação KRASG12C.
13 Jun, 2022 | 14:42hAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute
#ASCO22 – Estudo randomizado fase 2 | Ramucirumabe e pembrolizumabe vs. cuidado padrão no câncer de pulmão de não pequenas células avançado e previamente tratado com imunoterapia.
13 Jun, 2022 | 14:40hComentário: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network
Comentário no Twitter
📣 #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. https://t.co/M0zL95ddxD @ReckampK @DrRoyHerbstYale #lcsm
— Journal of Clinical Oncology (@JCO_ASCO) June 3, 2022
#ASCO22 – Estudo de braço único fase 2 | Bloqueio PD-1 no câncer retal localmente avançado com deficiência do reparo de incompatibilidade.
13 Jun, 2022 | 14:39hPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
#ASCO22 – Estudo de braço único fases 1-2 | Teclistamabe no mieloma múltiplo recidivante ou refratário.
13 Jun, 2022 | 14:38hTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Comentário no Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Estudo randomizado | Terapia tripla, transplante e manutenção até a progressão no mieloma.
13 Jun, 2022 | 14:37hTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute
Comentário no Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022
Estudo randomizado | Efeito de transferências intraoperatórias de cuidados anestésicos sobre mortalidade, reinternação e complicações pós-cirúrgicas entre adultos.
13 Jun, 2022 | 14:35hEffect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults: The HandiCAP Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Estudo relacionado: Association Between Handover of Anesthesia Care and Adverse Postoperative Outcomes Among Patients Undergoing Major Surgery – JAMA
Comentário no Twitter
In this RCT, among adults undergoing extended surgical procedures, there was no difference bw handover of anesthesia care compared w no handover of care in the primary outcome of mortality, readmission, & serious postoperative complications within 30 days.https://t.co/FpGFZk47x7
— JAMA (@JAMA_current) June 4, 2022
Estudo randomizado | Dispositivo assistido por computador melhora a detecção de adenomas na colonoscopia para rastreamento e vigilância.
13 Jun, 2022 | 14:34hComentário: Colonoscopy With a Computer-Aided Device Boosted Adenoma Detection — Use of the device led to a 27% increase in adenomas per colonoscopy versus standard procedure – MedPage Today (necessário cadastro gratuito)